The Biology of Healing

Understanding how the body protects, repairs, and restores itself—one biological system at a time.

Lesson 4

When Cells Forget to Die

We’ve spent the first three lessons talking about something most of us rarely stop to appreciate: your body is constantly maintaining itself.

Cells are being repaired. Old proteins are being recycled. Immune cells are patrolling the neighborhood. The endocannabinoid system is helping regulate communication, inflammation, stress responses, and balance. Long before anything appears on a scan, an enormous amount of biological housekeeping has already taken place.

But there’s another part of this maintenance system that’s every bit as remarkable.

Sometimes the healthiest thing a cell can do…

is die.

That probably sounds strange. We tend to think of cell death as something going wrong. But your body doesn’t. Cells aren’t supposed to live forever. When a cell becomes old, damaged, unnecessary, or potentially dangerous, biology has mechanisms that can essentially tell it:

Your work here is finished.

The cell dismantles itself in an orderly fashion, its components are cleared away, and surrounding tissue carries on.

The process is called apoptosis, or programmed cell death.

And without it, we wouldn’t stay healthy for very long.

Think about a tree in autumn. The tree doesn’t desperately cling to every leaf because losing a leaf must mean something terrible has happened. There is a season for growth and a season for letting go. Biology understands something we humans occasionally struggle with:

Keeping everything forever isn’t necessarily healthy.

Your cells operate under a similar principle.

Throughout life, cells accumulate damage. DNA gets injured. Replication mistakes occur. Environmental stress happens. Some damage can be repaired. Some cells can be salvaged. Others reach a point where continuing to replicate would create a greater problem than removing them.

That’s when the exit program becomes important.

Healthy cells contain molecular pathways capable of initiating their own controlled destruction when circumstances warrant it. The process is highly organized. Signals activate proteins called caspases, cellular structures are dismantled, DNA is fragmented, and the remains are packaged so they can be removed with relatively little disruption to surrounding tissue.

No explosion.

No biological crime scene.

Just an orderly departure.

Your body has been doing this your entire life.

And then we get to cancer.

One of the defining characteristics of cancer is not simply that abnormal cells grow too quickly. It’s that they can acquire the ability to resist the signals telling them to stop growing or die. The machinery that normally helps remove a damaged cell becomes altered, bypassed, suppressed, or ignored.

The cell that should have left the party refuses to go home.

Then it invites friends.

That’s when the problem becomes considerably more serious.

This is why apoptosis has become such an important area of cancer research. If malignant cells have learned ways to resist programmed death, researchers naturally want to understand whether those death pathways can be restored or reactivated.

And this is where our conversation about cannabinoids becomes particularly interesting.

THC Enters the Conversation

For decades, cannabis in oncology was discussed primarily in terms of symptom management: nausea, appetite, discomfort, sleep, and quality of life.

Those uses matter.

But they aren’t the entire cannabinoid story.

Laboratory research has repeatedly shown that THC can influence pathways involved in programmed cell death in certain cancer models. Research summarized by the National Cancer Institute describes cannabinoid-induced apoptosis in cultured glioma cells and tumor regression in animal glioma models, along with preclinical findings involving hepatocellular, breast, lung, and other cancer models.

Now think back to Lesson 2.

THC isn’t entering a body that has never seen cannabinoid signaling before. It is interacting with an existing biological network—the endocannabinoid system—including cannabinoid receptors and signaling pathways already involved in cellular regulation.

That distinction matters.

We’re not talking about a foreign chemical randomly poisoning everything it encounters.

We’re talking about molecular signaling.

And in some experimental cancer models, cannabinoid signaling appears capable of pushing malignant cells toward pathways that end in death.

That’s a much more fascinating story.

Researchers have described several mechanisms. Depending on the cancer model, cannabinoids have been associated with endoplasmic-reticulum stress, changes in ceramide signaling, autophagy, mitochondrial dysfunction, altered PI3K/AKT/mTOR signaling, cell-cycle arrest, and activation of apoptotic machinery. A 2024 review summarized evidence for cannabinoid effects on apoptosis, autophagy, proliferation, angiogenesis, and metastasis across experimental cancer systems.

That’s quite a résumé for a plant that spent most of the last century being discussed as though its greatest contribution to civilization was making people hungry for Doritos.

But here’s where things get even more interesting.

Some preclinical experiments suggest cannabinoids can affect malignant cells differently from normal cells. The NCI summarizes glioma research in which cannabinoids induced apoptosis in tumor cells while normal glial cells were comparatively protected in those experimental systems. That doesn’t mean cannabinoids universally distinguish cancer from healthy tissue, but it is one of the reasons this biology deserves serious investigation.

And THC isn’t the only cannabinoid involved.

CBD Isn’t Just Along for the Ride

We’ve talked about CBD primarily through the lens of inflammation and regulation, but its biology reaches considerably further.

CBD has also produced programmed cell death and antiproliferative effects across numerous laboratory cancer models through mechanisms that can differ from THC. Recent research continues to examine effects involving mitochondrial function, oxidative stress, calcium signaling, endoplasmic-reticulum stress, autophagy, apoptosis, and other regulated cell-death pathways.

That gives us a much more interesting way to think about combining cannabinoids.

THC and CBD aren’t necessarily doing identical jobs.

They’re interacting with overlapping biological terrain through different receptors and signaling pathways. In some preclinical glioblastoma research, combinations of THC and CBD have demonstrated greater antiproliferative activity than either cannabinoid alone.

That’s one reason cannabinoid ratios, concentrations, timing, delivery, tumor biology, and formulation matter so much. “Cannabis” isn’t one molecule, cancer isn’t one disease, and the human body isn’t one standardized laboratory dish.

Biology is always more complicated than the headline.

But complicated doesn’t mean unimportant.

It means we need to understand it better.

The Bigger Question

I think this is where people facing serious health challenges deserve a more complete conversation.

Cannabis should not be reduced to “something that helps cancer patients eat.“

That’s part of the story.

It isn’t the whole story.

There is legitimate preclinical research investigating cannabinoids and tumor-cell proliferation, apoptosis, autophagy, angiogenesis, invasion, inflammation, and other mechanisms relevant to cancer biology.

At the same time, we need to distinguish laboratory evidence from proof of clinical effectiveness in humans. Human evidence for cannabinoids as cancer-directed treatment remains limited, and current oncology guidelines do not consider cannabis an established anticancer therapy outside clinical trials.

Both statements can be true.

The laboratory biology can be compelling while the human clinical research remains incomplete.

That’s not a reason to stop asking questions.

It’s a reason to ask better ones.

Because somewhere underneath the politics, history, fear, hype, and arguments surrounding cannabis sits something much more interesting:

A cell.

A receptor.

A signal.

And a decision.

Grow.

Repair.

Stop.

Or die.

That is where the real conversation belongs.

The Biology

Apoptosis is an organized form of programmed cell death essential to normal development and tissue maintenance. When cellular damage becomes severe enough, internal or external signals can activate molecular cascades involving proteins such as caspases, ultimately dismantling the cell and allowing its components to be cleared.

Cancer cells frequently develop mechanisms that evade these death signals, which contributes to their survival and continued proliferation.

In multiple preclinical cancer models, THC, CBD, and other cannabinoids have affected pathways involved in apoptosis, autophagy, cell-cycle regulation, angiogenesis, and proliferation. The specific response varies substantially according to cancer type, cannabinoid, concentration, receptor expression, experimental conditions, and other biological factors.

These findings establish an important biological research question. They do not establish a universal cannabis treatment protocol for human cancer, and people undergoing cancer treatment should coordinate cannabinoid use with qualified clinicians because cannabinoids can have side effects and drug interactions.

Key Takeaway

Cancer isn’t simply a story about cells that grow too much. It’s also a story about cells that have learned ways to survive when biology would normally tell them to die.

Apoptosis is one of the body’s fundamental safeguards against damaged and unnecessary cells. The fact that cannabinoids can influence apoptotic and related cell-survival pathways in experimental cancer models gives us an important window into why the endocannabinoid system has become such an intriguing area of cancer research.

The question is no longer merely what cannabis makes us feel.

The more interesting question is:

What is cannabinoid signaling telling the cell?